Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

• Main Authors: António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto
• Format: Article
• Language: English
• Published: Elsevier 2017-01-01
• Series: Leukemia Research Reports
• Subjects: Acute myeloid leukemia; Elderly; Hypomethylating agents; Azacitidine
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213048916300486

Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.